{'Year': '2017', 'Season': 'Apr-Jun'}
Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.
To assess the feasibility of clinical pharmacist-led CYP2C19 genotype-guided P2Y<sub>12</sub> inhibitor antiplatelet drug therapy recommendations to cardiologists in an outpatient cardiology practice.